Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab combined with radiotherapy for first-line advanced malignant melanoma
ChiCTR2400082911Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cadonilimab in melanoma and acral lentiginous melanoma (ALM), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: progression-free survival. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
melanomaacral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on ChiCTR2400082911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082911.